A Randomized Trial of Nafamostat for Covid-19. Susan C Morpeth , Balasubramanian Venkatesh , James A Totterdell , Grace M McPhee , Robert K Mahar , Mark Jones , Methma Bandara , Lauren A Barina , Bhupendra K Basnet , Asha C Bowen , Andrew J Burke , Belinda Cochrane , Justin T Denholm , Ashesh Dhungana , Gregory J Dore , Ravindra Dotel , Eamon Duffy , Jack Dummer , Hong Foo , Timothy L Gilbey , Naomi E Hammond , Bernard J Hudson , Vivekanand Jha , Purnima R Jevaji , Oommen John , Rajesh Joshi , Gagandeep Kang , Baldeep Kaur , Seungtaek Kim , Santa Kumar Das , Jillian S Y Lau , Roberta Littleford , Julie A Marsh , Ian C Marschner , Gail Matthews , Michael J Maze , Colin J McArthur , James D McFadyen , James H McMahon , Zoe K McQuilten , James Molton , Jocelyn M Mora , Vijaybabu Mudaliar , Vi Nguyen , Matthew V N O'Sullivan , Suman Pant , Jaha E Park , David L Paterson , David J Price , Nigel Raymond , Megan A Rees , James O Robinson , Benjamin A Rogers , Wang-Shick Ryu , Joe Sasadeusz , Omar Shum , Thomas L Snelling , Christine Sommerville , Nanette Trask , Sharon R Lewin , Thomas E Hills , Joshua S Davis , Jason A Roberts , Steven Y C Tong NEJM evidence（2023）
摘要
A Randomized Trial of Nafamostat for Covid-19Nafamostat mesylate is a potent in vitro antiviral that inhibits the host transmembrane protease serine 2 enzyme used by SARS-CoV-2 for cell entry. Morpeth et al report the results of an open-label randomized clinical trial of nafamostat for noncritically ill patients with Covid-19.
更多 查看译文
AI 理解论文
溯源树
样例
